Alzinova AB Logo

Alzinova AB

Developing targeted immunotherapies, including a vaccine, for Alzheimer's disease.

ALZ | ST

Overview

Corporate Details

ISIN(s):
SE0007413455
LEI:
549300K3IMVT20EK2S13
Country:
Sweden
Address:
Pepparedsleden 1, 431 83 MÖLNDAL
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alzinova AB is a clinical-stage biopharmaceutical company specializing in the development of disease-modifying treatments for Alzheimer's disease. The company's research is centered on its proprietary AβCC Peptide™ technology, which enables the development of immunotherapies that specifically target neurotoxic amyloid-beta oligomers, a central cause of the disease. Alzinova's pipeline includes both active immunotherapies (vaccines) and passive immunotherapies (antibodies). Its lead candidate, ALZ-101, is a therapeutic vaccine in clinical development designed to be a highly specific treatment to prevent or slow the progression of Alzheimer's disease.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Alzinova AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Alzinova AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Alzinova AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-03 Tord Evert Sigfried Labuda Other Other 1,000,000 260,000.00 SEK
2025-04-03 Tord Evert Sigfried Labuda Other Buy 10,000 18,800.00 SEK
2025-04-02 Tord Evert Sigfried Labuda Other Buy 20,000 40,000.00 SEK
2024-12-16 Erik Kullgren Other Buy 10,000 34,400.00 SEK

Peer Companies

2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden
2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom
4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America
SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America
AARD
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America
ABBV
ABEONA THERAPEUTICS INC. Logo
Developing AAV-based cell and gene therapies for serious and rare diseases.
United States of America
ABEO
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden
ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom
ABDX

Talk to a Data Expert

Have a question? We'll get back to you promptly.